COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study
Kläser K., Molteni E., Graham M., Canas LS., Österdahl MF., Antonelli M., Chen L., Deng J., Murray B., Kerfoot E., Wolf J., May A., Fox B., Capdevila J., Aanensen DM., Abudahab K., Adams H., Adams A., Afifi S., Aggarwal D., Ahmad SSY., Aigrain L., Alcolea-Medina A., Alikhan N-F., Allara E., Amato R., Angyal A., Annett T., Aplin S., Ariani CV., Asad H., Ash A., Ashfield P., Ashford F., Atkinson L., Attwood SW., Auckland C., Aydin A., Baker DJ., Baker P., Balcazar CE., Ball J., Barrett JC., Barrow M., Barton E., Bashton M., Bassett AR., Batra R., Baxter C., Bayzid N., Beaver C., Beckett AH., Beckwith SM., Bedford L., Beer R., Beggs A., Bellis KL., Berry L., Bertolusso B., Best A., Betteridge E., Bibby D., Bicknell K., Binns D., Birchley A., Bird PW., Bishop C., Blacow R., Blakey V., Blane B., Bolt F., Bonfield J., Bonner S., Bonsall D., Boswell T., Bosworth A., Bourgeois Y., Boyd O., Bradley DT., Breen C., Bresner C., Breuer J., Bridgett S., Bronner IF., Brooks E., Broos A., Brown JR., Bucca G., Buchan SL., Buck D., Bull M., Burns PJ., Burton-Fanning S., Byaruhanga T., Byott M., Campbell S., Carabelli AM., Cargill JS., Carlile M., Carvalho SF., Casey A., Castigador A., Catalan J., Chalker V., Chaloner NJ., Chand M., Chappell JG., Charalampous T., Chatterton W., Chaudhry Y., Churcher CM., Clark G., Clarke P., Cogger BJ., Cole K., Collins J., Colquhoun R., Connor TR., Cook KF., Coombes J., Corden S., Cormie C., Cortes N., Cotic M., Cotton S., Cottrell S., Coupland L., Cox M., Cox A., Craine N., Crawford L., Cross A., Crown MR., Crudgington D., Cumley N., Curran T., Curran MD., da Silva Filipe A., Dabrera G., Darby AC., Davidson RK., Davies A., Davies RM., Davis T., de Angelis D., De Lacy E., de Oliveira Martins L., de Silva TI., Debebe J., Denton-Smith R., Dervisevic S., Dewar R., Dey J., Dias J., Dobie D., Dorman MJ., Downing F., Driscoll M., du Plessis L., Duckworth N., Durham J., Eastick K., Easton LJ., Eccles R., Edgeworth J., Edwards S., Bouzidi KE., Eldirdiri S., Ellaby N., Elliott S., Eltringham G., Ensell L., Erkiert MJ., Zamudio ME., Essex S., Evans JM., Evans C., Everson W., Fairley DJ., Fallon K., Fanaie A., Farr BW., Fearn C., Feltwell T., Ferguson L., Fina L., Flaviani F., Fleming VM., Forrest S., Foster-Nyarko E., Foulkes BH., Foulser L., Fragakis M., Frampton D., Francois S., Fraser C., Freeman TM., Fryer H., Fuchs M., Fuller W., Gajee K., Galai K., Gallagher A., Gallagher E., Gallagher MD., Gallis M., Gaskin A., Gatica-Wilcox B., Geidelberg L., Gemmell M., Georgana I., George RP., Gifford L., Gilbert L., Girgis ST., Glaysher S., Goldstein EJ., Golubchik T., Gomes AN., Gonçalves S., Goodfellow IG., Goodwin S., Goudarzi S., Gourtovaia M., Graham C., Graham L., Grant PR., Green LR., Green A., Greenaway J., Gregory R., Guest M., Gunson RN., Gupta RK., Gutierrez B., Haldenby ST., Hamilton WL., Hansford SE., Haque T., Harris KA., Harrison I., Harrison EM., Hart J., Hartley JA., Harvey WT., Harvey M., Hassan-Ibrahim MO., Heaney J., Helmer T., Henderson JH., Hesketh AR., Hey J., Heyburn D., Higginson EE., Hill V., Hill JD., Hilson RA., Hilvers E., Holden MTG., Hollis A., Holmes CW., Holmes N., Holmes AH., Hopes R., Hornsby HR., Hosmillo M., Houlihan C., Howson-Wells HC., Hsu SN., Hubb J., Huckson H., Hughes W., Hughes J., Hughes M., Hutchings S., Idle G., Illingworth CJ., Impey R., Irish-Tavares D., Iturriza-Gomara M., Izuagbe R., Jackson C., Jackson B., Jackson LM., Jackson KA., Jackson DK., Jahun AS., James V., James K., Jeanes C., Jeffries AR., Jeremiah S., Jermy A., John M., Johnson R., Johnson K., Johnston I., Jones O., Jones S., Jones H., Jones CR., Jones N., Joseph A., Judges S., Kay GL., Kay S., Keatley J-P., Keeley AJ., Kenyon A., Kermack LM., Khakh M., Kidd SP., Kimuli M., Kirk S., Kitchen C., Kitchman K., Knight BA., Koshy C., Kraemer MUG., Kumziene-Summerhayes S., Kwiatkowski D., Lackenby A., Laing KG., Lampejo T., Langford CF., Lavin D., Lawton AI., Lee JCD., Lee D., Lensing SV., Leonard S., Levett LJ., Le-Viet T., Lewis J., Lewis K., Liddle J., Liggett S., Lillie PJ., Lindsey BB., Lister MM., Livett R., Lo S., Loman NJ., Loose MW., Louka SF., Loveson KF., Lowdon S., Lowe H., Lowe HL., Lucaci AO., Ludden C., Lynch J., Lyons RA., Lythgoe K., Machin NW., MacIntyre-Cockett G., Mack A., Macklin B., Maclean A., Macnaughton E., Madona P., Maes M., Maftei L., Mahanama AIK., Mahungu TW., Mair D., Maksimovic J., Malone CS., Maloney D., Manesis N., Manley R., Mantzouratou A., Marchbank A., Mariappan A., Martincorena I., Nunez RTM., Mather AE., Maxwell P., Mayhew M., Mbisa T., McCann CM., McCarthy SA., McCluggage K., McClure PC., McCrone JT., McHugh MP., McKenna JP., McKerr C., McManus GM., McMurray CL., McMurray C., McNally A., Meadows L., Medd N., Megram O., Menegazzo M., Merrick I., Michell SL., Michelsen ML., Mirfenderesky M., Mirza J., Miskelly J., Moles-Garcia E., Moll RJ., Molnar Z., Monahan IM., Mondani M., Mookerjee S., Moore C., Moore J., Moore N., Moore C., Morcrette H., Morgan S., Morgan M., Mori M., Morriss A., Moses S., Mower C., Muir P., Mukaddas A., Munemo F., Munn R., Murray A., Murray LJ., Murray DR., Mutingwende M., Myers R., Nastouli E., Nebbia G., Nelson A., Nelson C., Nicholls S., Nichols J., Nicodemi R., Nomikou K., O’Grady J., O’Brien S., Odedra M., Ohemeng-Kumi N., Oliver K., Orton RJ., Osman H., O’Toole Á., Pacchiarini N., Padgett D., Page AJ., Park EJ., Park NR., Parker MD., Parmar S., Partridge DG., Pascall D., Patel A., Patel B., Paterson S., Payne BAI., Peacock SJ., Pearson C., Pelosi E., Percival B., Perkins J., Perry M., Pinckert ML., Platt S., Podplomyk O., Pohare M., Pond M., Pope CF., Poplawski R., Powell J., Poyner J., Prestwood L., Price A., Price JR., Prieto JA., Pritchard DT., Prosolek SJ., Pugh G., Pusok M., Pybus OG., Pymont HM., Quail MA., Quick J., Radulescu C., Raghwani J., Ragonnet-Cronin M., Rainbow L., Rajan D., Rajatileka S., Ramadan NA., Rambaut A., Ramble J., Randell PA., Randell P., Ratcliffe L., Raviprakash V., Raza M., Redshaw NM., Rey S., Reynolds N., Richter A., Robertson DL., Robinson E., Robson SC., Rogan F., Rooke S., Rowe W., Roy S., Rudder S., Ruis C., Rushton S., Ryan F., Saeed K., Samaraweera B., Sambles CM., Sanderson R., Sanderson T., Sang F., Sass T., Scher E., Scott G., Scott C., Sehmi J., Shaaban S., Shah D., Shaw J., Shelest E., Shepherd JG., Sheridan LA., Sheriff N., Shirley L., Sillitoe J., Silviera S., Simpson DA., Singh A., Singleton D., Skvortsov T., Sloan TJ., Sluga G., Smith K., Smith KS., Smith P., Smith DL., Smith L., Smith CP., Smith N., Smollett KL., Snell LB., Somassa T., Southgate J., Spellman K., Chapman MHS., Spurgin LG., Spyer MJ., Stanley R., Stanley W., Stanton TD., Starinskij I., Stockton J., Stonehouse S., Storey N., Studholme DJ., Sudhanva M., Swindells E., Taha Y., Tan NK., Tang JW., Tang M., Taylor BEW., Taylor JF., Taylor S., Temperton B., Templeton KE., Thomas C., Thomson L., Thomson EC., Thornton A., Thurston SAJ., Todd JA., Tomb R., Tong L., Tonkin-Hill G., Torok ME., Tovar-Corona JM., Trebes A., Trotter AJ., Tsatsani I., Turnbull R., Turtle L., Twohig KA., Umpleby H., Underwood AP., Vamos EE., Vasylyeva TI., Vattipally S., Vernet G., Vipond BB., Volz EM., Walsh S., Wang D., Warne B., Warwick-Dugdale J., Wastnedge E., Watkins J., Watson LK., Waugh S., Webster HJ., Weldon D., Westwick E., Whalley T., Wheeler H., Whitehead M., Whiteley M., Whitwham A., Wierzbicki C., Willford NJ., Williams L-A., Williams R., Williams C., Williams C., Williams CA., Williams RJ., Williams T., Williams C., Williamson KA., Wilson-Davies E., Witele E., Withell KT., Witney AA., Wolverson P., Wong N., Workman T., Wright V., Wright DW., Wyatt T., Wyllie S., Xu-McCrae L., Yavus M., Yaze G., Yeats CA., Yebra G., Yew WC., Young GR., Young J., Zarebski AE., Zhang P., Modat M., Hammers A., Spector TD., Steves CJ., Sudre CH., Ourselin S., Duncan EL.
Abstract The Delta (B.1.617.2) variant was the predominant UK circulating SARS-CoV-2 strain between May and December 2021. How Delta infection compares with previous variants is unknown. This prospective observational cohort study assessed symptomatic adults participating in the app-based COVID Symptom Study who tested positive for SARS-CoV-2 from May 26 to July 1, 2021 (Delta overwhelmingly the predominant circulating UK variant), compared (1:1, age- and sex-matched) with individuals presenting from December 28, 2020 to May 6, 2021 (Alpha (B.1.1.7) the predominant variant). We assessed illness (symptoms, duration, presentation to hospital) during Alpha- and Delta-predominant timeframes; and transmission, reinfection, and vaccine effectiveness during the Delta-predominant period. 3581 individuals (aged 18 to 100 years) from each timeframe were assessed. The seven most frequent symptoms were common to both variants. Within the first 28 days of illness, some symptoms were more common with Delta versus Alpha infection (including fever, sore throat, and headache) and some vice versa (dyspnoea). Symptom burden in the first week was higher with Delta versus Alpha infection; however, the odds of any given symptom lasting ≥ 7 days was either lower or unchanged. Illness duration ≥ 28 days was lower with Delta versus Alpha infection, though unchanged in unvaccinated individuals. Hospitalisation for COVID-19 was unchanged. The Delta variant appeared more (1.49) transmissible than Alpha. Re-infections were low in all UK regions. Vaccination markedly reduced the risk of Delta infection (by 69-84%). We conclude that COVID-19 from Delta or Alpha infections is similar. The Delta variant is more transmissible than Alpha; however, current vaccines showed good efficacy against disease. This research framework can be useful for future comparisons with new emerging variants.
